<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82951">
  <stage>Registered</stage>
  <submitdate>1/07/2008</submitdate>
  <approvaldate>4/08/2008</approvaldate>
  <actrnumber>ACTRN12608000389303</actrnumber>
  <trial_identification>
    <studytitle>Efficacy of blood glucose self-monitoring and intensive education in patients with type 2 diabetes not receiving insulin: a pilot study</studytitle>
    <scientifictitle>Efficacy of blood glucose self-monitoring and intensive education in patients with type 2 diabetes not receiving insulin: a pilot study</scientifictitle>
    <utrn />
    <trialacronym>ROSES</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>non insulin dependent diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>self monitoring of blood glucose (SMBG) plus intensive education.
SMBG: patients will receive specific educational interventions to teach them how to perform SMBG, how to modify diet and level of physical activity according to blood glucose levels, and the actions to be undertaken in case of abnormal values (hypoglycemia, particularly elevated glucose levels). Patients will be provided a glucometer and all the material necessary for SMBG. There will be 2 SMBG educational sessions, the first one will be at randomization (150 minutes in duration), and the second session after 1 week (20 minutes in duration).
Intensive education: patients will be also instructed to modify their lifestyle habits (diet, physical activity) in order to reach specific goals: weight reduction &gt;=5%, reduction in fat consumption (&lt;30% of daily caloric intake), reduction in saturated fat intake (&lt;10% of daily caloric intake), increase in fiber intake (&gt;=15 gr/1000 Kcal), regular physical activity (&gt;=30 min/daily; &gt;=4 hours/week). The intensive educational sessions will be at the randomization (60 minutes), and after 3 months (60 minutes).
The subjects in the intervention group receive both the SMBG and intensive education and standard care too.

The educational approach will be standardized and provided by specialist nurses after specific training.</interventions>
    <comparator>standard care: all the patients will receive information about diabetes and its complications, the importance of metabolic control, diabetes self-care, diabetes treatment, and the importance of diet and physical activity. The patients will receive standard care during all the trial (6 months from the randomization)</comparator>
    <control>Active</control>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>improvement of metabolic control expressed as HbA1c</outcome>
      <timepoint>at 6 months after randomization</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>percentage of patients needing therapy modifications. The protocol describes an algorithm (based on pre prandial glucose levels) that suggests to the investigators when the patient needs therapy modifications.</outcome>
      <timepoint>at six months after randomization</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>percentage of patients reaching target HbA1c (i.e. &lt;7%)</outcome>
      <timepoint>at six months after randomization</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>reduction in prandial blood glucose excursion</outcome>
      <timepoint>at six months after randomization</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with Type 2 diabetes (known diabetes or new diagnosis) seen for the first time in the diabetes outpatient clinic;
Patients on treatment with oral hypoglycaemic agents (OHA) monotherapy (i.e. metformin alone or sulphonyloureas alone or thiazolidinediones (TZDs) alone);
No need for insulin treatment; 
Male and female patients, aged between 45-75 years; 
Hba1c values between 7% and 9% included (considering a value of 6.0% as the upper limit of normal value)
No experience of self monitoring of blood glucose (SMBG) in the previous 12 months (SMBG performed with a frequency of &lt; 1 times/week)
Ability and willingness to comply with all study requirements
Signature of consent form</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>insulin therapy or more than one oral hypoglycaemic agents (OHA);
need of self monitoring of blood glucose (SMBG);
concomitant serious illnesses causing a reduction of life expectancy;
physical or mental problems preventing the self monitoring of blood glucose (SMBG);
patient management shared with general practitioner (GP).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by phone</concealment>
    <sequence>Permuted block randomisation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>24/10/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Consorzio Mario Negri Sud</primarysponsorname>
    <primarysponsoraddress>Via Nazionale, 8/a
66030 Santa Maria Imbaro (CH)</primarysponsoraddress>
    <primarysponsorcountry>Italy</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>LifeScan, Scotland Ltd</fundingname>
      <fundingaddress>Beechwood Park North
Inverness
Scotland
IV2 3ED</fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Aim of this pilot study is to evaluate the validity and feasibility of an educational approach involving nurses, combined with self monitoring blood glucose (SMBG), aimed at lifestyle modification and timely changes in therapy, when needed.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comitato Etico dell'Azienda Ospedaliera Sant'Anna di Como</ethicname>
      <ethicaddress>Via Napoleona, 60
22100 Como</ethicaddress>
      <ethicapprovaldate>22/03/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Comitato Etico Sperimentazione Clinica Medicinali della Ausl 8 di Arezzo</ethicname>
      <ethicaddress>Via Curtatone, 54
52100 Arezzo</ethicaddress>
      <ethicapprovaldate>16/03/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Comitato Etico per la Sperimentazione Clinica della provincia di Padova</ethicname>
      <ethicaddress>Via Berchet, 10 
35131  Padova</ethicaddress>
      <ethicapprovaldate>15/03/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Comitato Etico per la Sperimentazione Clinica dei Farmaci della AUSL di Pescara</ethicname>
      <ethicaddress>c/o Direzione Sanitaria P.O. Pescara
Via Fonte Romana, 8
65100 Pescara</ethicaddress>
      <ethicapprovaldate>22/03/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Monica Franciosi</name>
      <address>Dept. Clinical Pharmacology and Epidemiology
Consorzio Mario Negri Sud
Via Nazionale, 8/a
66030 S. Maria Imbaro (CH)</address>
      <phone>+39 0872 570264</phone>
      <fax>+39 0872 570263</fax>
      <email>franciosi@negrisud.it</email>
      <country>Italy</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Miriam Valentini</name>
      <address>Clinical research management and monitoring
Dept. Clinical Pharmacology and Epidemiology
Consorzio Mario Negri Sud
Via Nazionale, 8/a
66030 S. Maria Imbaro (CH)</address>
      <phone>+39 0872 570311</phone>
      <fax>+39 0872 570316</fax>
      <email>valentini@negrisud.it</email>
      <country>Italy</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Miriam Valentini</name>
      <address>Clinical research management and monitoring
Dept. Clinical Pharmacology and Epidemiology
Consorzio Mario Negri Sud
Via Nazionale, 8/a
66030 S. Maria Imbaro (CH)</address>
      <phone>+39 0872 570311</phone>
      <fax>+39 0872 570316</fax>
      <email>valentini@negrisud.it</email>
      <country>Italy</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>